Genprex to Showcase Promising Data on Reqorsa® for Lung Cancer Treatment at AACR-NCI-EROTC Conference

Genprex to Present at prestigious Cancer Conference

Genprex, Inc. is making headlines as it gears up to showcase its lead product candidate, Reqorsa® Gene Therapy, at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics. This event is slated for October 22-26, 2025, in Boston, Massachusetts, and promises to highlight significant preclinical data regarding the effectiveness of Reqorsa in treating ALK-EML4 positive translocated non-small cell lung cancer (NSCLC).

The excitement surrounding this presentation is palpable as Genprex prepares to share the study’s outcomes, which show that Reqorsa effectively induces apoptosis in ALK positive lung cancer cells, a subgroup that predominantly affects young, non-smoking individuals. Ryan Confer, President and CEO of Genprex, expressed his enthusiasm for the upcoming presentation, stating, "We are thrilled that our collaborators have once again been selected to present positive preclinical data on the use of Reqorsa and its ability to induce apoptosis in ALK positive lung cancer. This validates Reqorsa's potential for treating various cancers and underscores the importance of our ongoing research into its combined use with ALK inhibitors."

The highlight of Genprex’s contributions will be a poster titled ‘Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies,’ set to unveil insights from the collaboration between Genprex and the University of Michigan Rogel Cancer Center. Scheduled for presentation on October 25, 2025, the study dives deep into how the TUSC2 tumor suppressor gene employed in Reqorsa interacts with cancer cells, aiming to improve treatment outcomes for lung cancer patients.

The poster details findings from a Sponsored Research Agreement between Genprex and the Rogel Cancer Center, initiated in October 2024. This agreement focuses on the potential synergistic effects of TUSC2 in combination with ALK inhibitors, thus paving the way for more effective treatments for ALK-EML4 positive translocated lung cancer patients.

Moreover, Genprex's affiliation with ALK Positive, a non-profit organization dedicated to enhancing the quality of life for ALK-positive lung cancer patients, signifies a broad commitment to advancing research and developing potent therapies for this patient population. This partnership helps bolster fundraising for oncology research and patient support initiatives, creating a stronger network within the cancer research community.

In the laboratory setting, Reqorsa operates as a marvel of modern medicine—encapsulating the TUSC2 gene within lipid nanoparticles, maximizing its ability to target and penetrate cancer cells while minimizing effects on healthy tissue. Importantly, studies indicate that TUSC2 uptake in tumor cells is significantly higher than in normal cells, typically by 10 to 33 times post-treatment, evidencing its potential for targeted therapy.

Genprex, a clinical-stage gene therapy company, focuses on developing groundbreaking therapies for patients suffering from cancer and diabetes. The company utilizes cutting-edge technologies to introduce disease-fighting genes that offer promising alternative treatment options for individuals with limited choices.

The company's structure rests on its proprietary Oncoprex® Delivery System, leveraging lipid-based nanoparticles for efficient gene transfer therapies. Beyond its oncology innovations, Genprex is also advancing gene therapy treatment options for diabetes, signifying its broad scope in biomedicine. The heart of Genprex’s strategy involves partnerships with renowned research institutions and collaborative endeavors to propel its investigational drug candidates while addressing crucial patient needs.

As the conference approaches, Genprex continues to encourage stakeholders and interested parties to stay updated via its website and social media channels, underlining its commitment to transparency and engagement.

The presentation of this preclinical data could mark a pivotal moment for Genprex, framing Reqorsa as a competitive solution in the ongoing battle against lung cancer. Investors and clinicians eagerly await the deployment of this innovative therapy as Genprex strengthens its promise of delivering life-changing treatments that better the lives of patients confronted with daunting health adversities.